News
ASCO GU 2025 lead-in phase results of the ARAMON trial assessing darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback